Sachi Bio won Phase IIE and Phase III contracts from the NASA Human Research Program to continue advancement of the Neurotherapeutic program to develop Neurological countermeasures for long-term space travel.
This is builds on the recent successes of Sachi Bio's lead candidates that have been shown to be effective in a range of progressive neurodegenerative disease models including Alzheimer's disease, aging, ALS, Multiple sclerosis, and Prion disease. Additionally, Sachi Bio offers a strong drug-discovery platform with multiple therapeutic leads in the pipeline. Multiple publications from independent researchers in the Journal of Neuroinflammation, and ACS Chemical Neuroscience provide strong evidence of neuroprotection.
Some of Sachi Bio's recent publications:
Devin Wahl, Sydney J. Risen, Shelby C. Osburn, Tobias Emge, Sadhana Sharma, Vincenzo S. Gilberto, Anushree Chatterjee, Prashant Nagpal, Julie A. Moreno, Thomas J. LaRocca* (2024). Journal of Neuroinflammation 21 (182).
Sadhana Sharma, Sydney Risen, Vincenzo S. Gilberto, Sean Boland, Anushree Chatterjee, Julie A. Moreno, and, Prashant Nagpal* (2024). ACS Chemical Neuroscience 15, 7, 1596–1608.
Sydney J. Risen, Sean W. Boland, Sadhana Sharma, Grace M. Weisman, Payton M. Shirley, Amanda S. Latham, Arielle J. D. Hay, Vincenzo S. Gilberto, Amelia D. Hines, Stephen Brindley, Jared M. Brown, Stephanie McGrath, Anushree Chatterjee, Prashant Nagpal, and, Julie A. Moreno* (2024). ACS Chemical Neuroscience 15, 7, 1533-1547.
Sadhana Sharma, Curtis Borski, Jessica Hanson, Micklaus A. Garcia, Christopher D. Link, Charles Hoeffer, Anushree Chatterjee, and ,Prashant Nagpal* (2022). ACS Chemical Neuroscience 2022, 13, 23, 3247–3256.
Colleen M Courtney, Sadhana Sharma, Christina Fallgren, Michael M Weil, Anushree Chatterjee, Prashant Nagpal* (2022). Life Sciences in Space Research, 35, 127-39.